Profile picture

Miss Myrthe Van Der Heide

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))
Membership: ESC Professional Member
Follow
Logo ESC

Contributor content

Evaluating the predictive value of late gadolinium enhancement for major ventricular arrhythmia in phospholamban p.(Arg14del)-positive individuals.
Presentation
Evaluating the predictive value of late gadolinium enhancement for major ventricular arrhythmia in phospholamban p.(Arg14del)-positive individuals.
Predicting heart failure in phospholamban p.(Arg14del)-positive individuals using vectorcardiographic information
Presentation
Predicting heart failure in phospholamban p.(Arg14del)-positive individuals using vectorcardiographic information
Time-varying cox model for heart failure prediction in phospholamban p.(Arg14del)-positive individuals
Presentation
Time-varying cox model for heart failure prediction in phospholamban p.(Arg14del)-positive individuals
The impact of comorbidities and substance use on heart failure events and major ventricular arrhythmias in phospholamban p.(Arg14del) positive individuals.
Presentation
The impact of comorbidities and substance use on heart failure events and major ventricular arrhythmias in phospholamban p.(Arg14del) positive individuals.
New joint model for the dynamic prediction of heart failure in phospholamban (PLN) p.(Arg14del) positive individuals
Presentation
New joint model for the dynamic prediction of heart failure in phospholamban (PLN) p.(Arg14del) positive individuals
The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
Presentation
The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
Longitudinal validation of the phospholamban (PLN) p.Arg14del risk model
Presentation
Longitudinal validation of the phospholamban (PLN) p.Arg14del risk model

ESC 365 is supported by